Table 6.
Studies on the use of BoNT-A therapy in postherpetic neuralgia.
| First Author [Ref.] | Type of Study | n | BoNT-A Doses | Follow-Up | Retreatment | Results |
|---|---|---|---|---|---|---|
| Ding [113], 2017 | Prospective | 58 | 50 to 100 | 2 weeks 1, 3, 6 months |
No | 75% of patients improved (Variable VAS, NPS reduction) |
| Jain [112], 2017 | Case report | 2 | 500 units Dysport diluted with 5 mL of normal saline, making a concentration of 100 units/mL | 1, 2, 4, 8, 12, 16 weeks | No | VAS for pain decreased from 9, 10 to 1 |
| Moon [118], 2016 | Case report | 2 | 50 U BoNT-A and bupivacaine 0.1% injected under ultrasound guide in brachial plexus | 5 months | No | VAS for pain decreased from 8 to 2, 3 |
| Li [110], 2015 | Case report (ophthalmic) | 1 | 100 U of BoNT-A in the orbital region (subcutaneous) | 6 months | No | VAS for pain decreased from 8–9 to 2–3 |
| Apalla [115], 2013 | Randomized, double-blind, placebo-controlled trial | 29 (4 postherpetic) | 20, 190 U of BoNT-A intradermally | 16 weeks | No | VAS decreasing |
| Emad [114], 2011 | interventional study | 15U per 10 cm2 (The amount of toxin was different for every patient: not reported) intradermally |
2, 4 weeks | No | VAS decreasing | |
| Xiao [109], 2010 | Randomized, double-blind, placebo-controlled trial | 60 | 5 U/mL of BoNT-A vs. 0.5% of lidocaine vs. 0.9% of saline | 3 months | No | Decrease in VAS score and improving in sleep hours superior to control group |
| Sotiriou [108], 2009 | Case reports | 3 | 100 U of BoNT-A in 4 mL of saline; subcutaneous in chessboard pattern | 12 weeks | No | Decrease in VAS score |
| Liu [116], 2006 | Case report | 1 | 100 U of BoNT-A injected in a fanning pattern | 9 months | No | VAS pain reduction from 10 to 1 |